Israeli Biotech Clearmind Medicine Announces Pre-Clinical Results Treating Major Depression With A Novel Ketamine-Based Compound

Author: Bill Haddad | January 31, 2023 10:05am

Clearmind Medicine Inc. (NASDAQ:CMND) (CSE:CMND), (FSE: CWY) ("Clearmind" or "the Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that as part of its ongoing collaboration with the Bar-Ilan University, Israel and Professor Gal Yadid, from the Gonda Multidisciplinary Brain Research Center, a new pre-clinical trial (the "trial") resulted in positive outcomes in relation to treating Major Depressive Disorder ("MDD").

Posted In: CMND CSE:CMND